Form 4: United Therapeutics CFO Executes Stock Option Plan

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

Summary

• CFO James Edgemond exercised 10,000 stock options at a strike price of $135.42.
• Following the exercise, the reporting person sold the acquired shares in multiple tranches at weighted average prices ranging from $569.62 to $576.62.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025.
• The reporting person retains 18,876 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a pre-planned, routine financial transaction by an executive.

Positives

• The transactions were executed under a pre-planned Rule 10b5-1 program, indicating the sales were not based on non-public information.
• The executive maintains a significant remaining equity stake of 18,876 shares.

Negatives

• The executive reduced their direct beneficial ownership of common stock through the sale of the exercised options.

Risks

• None identified; this is a routine disclosure of executive compensation and equity management.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine 10b5-1 sales by C-suite executives are standard practice for liquidity and tax management and generally do not signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to sell shares while avoiding potential insider trading liability.
• The volume of shares sold relative to the executive's total holdings is consistent with typical executive compensation liquidation patterns.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and disclosed in accordance with SEC regulations.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, CFO, Stock Options, Rule 10b5-1